<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="594">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153421</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-0001</org_study_id>
    <nct_id>NCT05153421</nct_id>
  </id_info>
  <brief_title>Evaluation of All'InCath in Peripheral Vasculature Percutaneous Transluminal Angioplasty.</brief_title>
  <acronym>CBC035M</acronym>
  <official_title>Clinical Evaluation of the All'InCath CBC 035M When Used for Peripheral Vasculature Percutaneous Transluminal Angioplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NexStep Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NexStep Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety, efficacy, performance and&#xD;
      advantages (e.g. decrease of procedure time, decrease of radiation time, decrease of the&#xD;
      amount of injected contrast, delivery and ease of use) of a novel balloon catheter that&#xD;
      combines angiography and angioplasty capabilities.&#xD;
&#xD;
      Since the device is already FDA approved, the objective is focused on performance evaluation&#xD;
      including physician operators' feedback.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>immediately post-procedure</time_frame>
    <description>Periprocedural Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance and effectiveness of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>immediately post-procedure</time_frame>
    <description>Vascular patency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>Time of Procedure</time_frame>
    <description>Duration of the PTA procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the function of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>During Procedure</time_frame>
    <description>Investigator opinion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency and Safety of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>During Procedure</time_frame>
    <description>Level of radiation exposure during the PTA (mGy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and performance of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>During Procedure</time_frame>
    <description>Dose of injected contrast medium at the targeted location (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the All'InCath Contrast Balloon Catheter 035M</measure>
    <time_frame>3 days</time_frame>
    <description>Post procedural adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Interventional - Angioplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angioplasty and angiography procedures with experimental medical device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>All'inCath Balloon</intervention_name>
    <description>Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography</description>
    <arm_group_label>Interventional - Angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide Informed Consent&#xD;
&#xD;
          -  Can also be executed by the legal designated representative or the witness&#xD;
&#xD;
          -  As per the Principal Investigator's practices as per standard of care, the subject is&#xD;
             indicated for PTA in the peripheral vasculature, including iliac, femoral, popliteal,&#xD;
             and renal arteries, and any treatment of obstructive lesions of native or synthetic&#xD;
             arteriovenous dialysis fistulae.&#xD;
&#xD;
          -  Male or female &gt;18 years old.&#xD;
&#xD;
          -  Life expectancy &gt;1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable coronary artery disease or any other uncontrolled comorbidity.&#xD;
&#xD;
          -  Myocardial infarction or stroke within two (2) months before baseline evaluation.&#xD;
&#xD;
          -  Previous peripheral bypass or procedure that includes the target vessel.&#xD;
&#xD;
          -  Known, untreated allergy or other contraindications to contrast agents or medications&#xD;
             used during or after PTA.&#xD;
&#xD;
          -  Non-correctable bleeding diathesis, platelet dysfunction, thrombocytopenia, or any&#xD;
             other known coagulopathy.&#xD;
&#xD;
          -  The use of antiplatelet or anticoagulant therapy is contraindicated.&#xD;
&#xD;
          -  Any planned major surgical or interventional procedure within 30 days after the study&#xD;
             procedure.&#xD;
&#xD;
          -  Females who are breast-feeding or child-bearing potential and not using a medically&#xD;
             reliable method of contraception (as defined below) for the entire study duration:&#xD;
&#xD;
          -  medically reliable contraception defined as: oral, injectable, or implantable&#xD;
             contraceptives, intrauterine contraceptive devices, or those not using another method&#xD;
             deemed by the Investigator to be sufficiently reliable.&#xD;
&#xD;
          -  subjects who are surgically sterilized / hysterectomized or post-menopausal for longer&#xD;
             than two (2) years are not considered childbearing potential.&#xD;
&#xD;
          -  Positive pregnancy test result in women of child bearing potential or is&#xD;
             breast-feeding.&#xD;
&#xD;
          -  Incapacitated individuals and those with psychiatric disorders that could interfere&#xD;
             with the provision of informed consent, completion of tests, therapy, follow-up or&#xD;
             general study compliance.&#xD;
&#xD;
          -  Participation in another study with investigational drug or device within the 30 days&#xD;
             preceding and during the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Thaveau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geprovas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Urbain</last_name>
    <phone>611724585</phone>
    <phone_ext>0033</phone_ext>
    <email>purbain@nexstepmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Marceau</last_name>
    <phone>5819987754</phone>
    <email>dmarceau@nexstepmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Thaveau, MD, PhD</last_name>
      <phone>369550927</phone>
      <phone_ext>0033</phone_ext>
      <email>fabien.thaveau@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien Thaveau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nabil Chakfe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence Bruyns, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Del Tatto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Lejay, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Georg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

